Copyright Reports & Markets. All rights reserved.

Global Vaccine for Non-infectious Meningitis Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Vaccine for Non-infectious Meningitis Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Vaccine for Non-infectious Meningitis Market Size Growth Rate by Product
      • 1.4.2 Polysaccharide Vaccines
      • 1.4.3 Conjugate Vaccines
      • 1.4.4 Combination Vaccines
      • 1.4.5 Men B Vaccines
    • 1.5 Market by End User
      • 1.5.1 Global Vaccine for Non-infectious Meningitis Market Size Growth Rate by End User
      • 1.5.2 Meningitis
      • 1.5.3 Septicemia
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Vaccine for Non-infectious Meningitis Market Size
      • 2.1.1 Global Vaccine for Non-infectious Meningitis Revenue 2014-2025
      • 2.1.2 Global Vaccine for Non-infectious Meningitis Sales 2014-2025
    • 2.2 Vaccine for Non-infectious Meningitis Growth Rate by Regions
      • 2.2.1 Global Vaccine for Non-infectious Meningitis Sales by Regions
      • 2.2.2 Global Vaccine for Non-infectious Meningitis Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Vaccine for Non-infectious Meningitis Sales by Manufacturers
      • 3.1.1 Vaccine for Non-infectious Meningitis Sales by Manufacturers
      • 3.1.2 Vaccine for Non-infectious Meningitis Sales Market Share by Manufacturers
      • 3.1.3 Global Vaccine for Non-infectious Meningitis Market Concentration Ratio (CR5 and HHI)
    • 3.2 Vaccine for Non-infectious Meningitis Revenue by Manufacturers
      • 3.2.1 Vaccine for Non-infectious Meningitis Revenue by Manufacturers (2014-2019)
      • 3.2.2 Vaccine for Non-infectious Meningitis Revenue Share by Manufacturers (2014-2019)
    • 3.3 Vaccine for Non-infectious Meningitis Price by Manufacturers
    • 3.4 Vaccine for Non-infectious Meningitis Manufacturing Base Distribution, Product Types
      • 3.4.1 Vaccine for Non-infectious Meningitis Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Vaccine for Non-infectious Meningitis Product Type
      • 3.4.3 Date of International Manufacturers Enter into Vaccine for Non-infectious Meningitis Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Vaccine for Non-infectious Meningitis Sales by Product
    • 4.2 Global Vaccine for Non-infectious Meningitis Revenue by Product
    • 4.3 Vaccine for Non-infectious Meningitis Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Vaccine for Non-infectious Meningitis Breakdown Data by End User

    6 North America

    • 6.1 North America Vaccine for Non-infectious Meningitis by Countries
      • 6.1.1 North America Vaccine for Non-infectious Meningitis Sales by Countries
      • 6.1.2 North America Vaccine for Non-infectious Meningitis Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Vaccine for Non-infectious Meningitis by Product
    • 6.3 North America Vaccine for Non-infectious Meningitis by End User

    7 Europe

    • 7.1 Europe Vaccine for Non-infectious Meningitis by Countries
      • 7.1.1 Europe Vaccine for Non-infectious Meningitis Sales by Countries
      • 7.1.2 Europe Vaccine for Non-infectious Meningitis Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Vaccine for Non-infectious Meningitis by Product
    • 7.3 Europe Vaccine for Non-infectious Meningitis by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Vaccine for Non-infectious Meningitis by Countries
      • 8.1.1 Asia Pacific Vaccine for Non-infectious Meningitis Sales by Countries
      • 8.1.2 Asia Pacific Vaccine for Non-infectious Meningitis Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Vaccine for Non-infectious Meningitis by Product
    • 8.3 Asia Pacific Vaccine for Non-infectious Meningitis by End User

    9 Central & South America

    • 9.1 Central & South America Vaccine for Non-infectious Meningitis by Countries
      • 9.1.1 Central & South America Vaccine for Non-infectious Meningitis Sales by Countries
      • 9.1.2 Central & South America Vaccine for Non-infectious Meningitis Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Vaccine for Non-infectious Meningitis by Product
    • 9.3 Central & South America Vaccine for Non-infectious Meningitis by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Vaccine for Non-infectious Meningitis by Countries
      • 10.1.1 Middle East and Africa Vaccine for Non-infectious Meningitis Sales by Countries
      • 10.1.2 Middle East and Africa Vaccine for Non-infectious Meningitis Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Vaccine for Non-infectious Meningitis by Product
    • 10.3 Middle East and Africa Vaccine for Non-infectious Meningitis by End User

    11 Company Profiles

    • 11.1 Serum Institute (India)
      • 11.1.1 Serum Institute (India) Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Serum Institute (India) Vaccine for Non-infectious Meningitis Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Serum Institute (India) Vaccine for Non-infectious Meningitis Products Offered
      • 11.1.5 Serum Institute (India) Recent Development
    • 11.2 Sanofi SA (France)
      • 11.2.1 Sanofi SA (France) Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Sanofi SA (France) Vaccine for Non-infectious Meningitis Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Sanofi SA (France) Vaccine for Non-infectious Meningitis Products Offered
      • 11.2.5 Sanofi SA (France) Recent Development
    • 11.3 Pfizer (USA)
      • 11.3.1 Pfizer (USA) Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Pfizer (USA) Vaccine for Non-infectious Meningitis Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Pfizer (USA) Vaccine for Non-infectious Meningitis Products Offered
      • 11.3.5 Pfizer (USA) Recent Development
    • 11.4 Nuron Biotech (USA)
      • 11.4.1 Nuron Biotech (USA) Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Nuron Biotech (USA) Vaccine for Non-infectious Meningitis Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Nuron Biotech (USA) Vaccine for Non-infectious Meningitis Products Offered
      • 11.4.5 Nuron Biotech (USA) Recent Development
    • 11.5 JN-International Medical (USA)
      • 11.5.1 JN-International Medical (USA) Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 JN-International Medical (USA) Vaccine for Non-infectious Meningitis Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 JN-International Medical (USA) Vaccine for Non-infectious Meningitis Products Offered
      • 11.5.5 JN-International Medical (USA) Recent Development

    12 Future Forecast

    • 12.1 Vaccine for Non-infectious Meningitis Market Forecast by Regions
      • 12.1.1 Global Vaccine for Non-infectious Meningitis Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Vaccine for Non-infectious Meningitis Revenue Forecast by Regions 2019-2025
    • 12.2 Vaccine for Non-infectious Meningitis Market Forecast by Product
      • 12.2.1 Global Vaccine for Non-infectious Meningitis Sales Forecast by Product 2019-2025
      • 12.2.2 Global Vaccine for Non-infectious Meningitis Revenue Forecast by Product 2019-2025
    • 12.3 Vaccine for Non-infectious Meningitis Market Forecast by End User
    • 12.4 North America Vaccine for Non-infectious Meningitis Forecast
    • 12.5 Europe Vaccine for Non-infectious Meningitis Forecast
    • 12.6 Asia Pacific Vaccine for Non-infectious Meningitis Forecast
    • 12.7 Central & South America Vaccine for Non-infectious Meningitis Forecast
    • 12.8 Middle East and Africa Vaccine for Non-infectious Meningitis Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Vaccine for Non-infectious Meningitis Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      Meningococcal conjugate vaccine is used to prevent infection caused by meningococcal bacteria.
      The global Vaccine for Non-infectious Meningitis market is valued at 1 million US$ in 2018 and will reach 2 million US$ by the end of 2025, growing at a CAGR of 12.0% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Vaccine for Non-infectious Meningitis market based on company, product type, end user and key regions.

      This report studies the global market size of Vaccine for Non-infectious Meningitis in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Vaccine for Non-infectious Meningitis in these regions.
      This research report categorizes the global Vaccine for Non-infectious Meningitis market by top players/brands, region, type and end user. This report also studies the global Vaccine for Non-infectious Meningitis market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Serum Institute (India)
      Sanofi SA (France)
      Pfizer (USA)
      Nuron Biotech (USA)
      JN-International Medical (USA)

      Market size by Product
      Polysaccharide Vaccines
      Conjugate Vaccines
      Combination Vaccines
      Men B Vaccines
      Market size by End User
      Meningitis
      Septicemia
      Others

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Vaccine for Non-infectious Meningitis market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Vaccine for Non-infectious Meningitis market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Vaccine for Non-infectious Meningitis companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Vaccine for Non-infectious Meningitis submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Vaccine for Non-infectious Meningitis are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Vaccine for Non-infectious Meningitis market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now